By combining the technology of silicon microfabrication with traditional medical device design Temari is developing two next generation products addressing unmet needs, Enfold for aneurysm closure and Divera for flow diversion.
The FDA deems there is a critical need for further advancements in minimally invasive treatment of cerebral aneurysms. These new endovascular treatments qualify for US FDA 510(k) fast track status, lowering the barrier for the introduction of a new device.
The device expands from a highly compressed state to fill the volume of the aneurysm sac, promote rapid peri-procedural stasis and then thrombosis to “seal the neck” of the aneurysm.
The device offers a unique closed cell design for optimal porosity with options to be used alone or in combination with ENFOLD for basal aneurysms.
We are a team of veterans of the semiconductor and medical device industries with an exclusively licensed technology platform that represents a paradigm shift in medical device manufacturing.
By applying semiconductor thin film manufacturing techniques to fabricate endovascular devices, we are introducing a new biocompatible material to address the limitations of existing products.
Multiple patents filed covering a broad range of device features and methods. We have secured initial seed funding and have successfully developed initial concepts.